Fragile X Syndrome – Pipeline Review, H2 2020
Fragile X Syndrome – Pipeline Review, H2 2020, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.
Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.
Fragile X Syndrome – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 3, 21 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
– The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Anavex Life Sciences Corp
Anima Biotech Inc
Autifony Therapeutics Ltd
Confluence Pharmaceuticals LLC
DRI Biosciences Corp
Epigen Biosciences Inc
GW Pharmaceuticals Plc
Hua Medicine Shanghai Ltd
Neuren Pharmaceuticals Ltd
Neuron Biopharma SA
Neurotrope Bioscience Inc
Ovid Therapeutics Inc
Prilenia Therapeutics Development Ltd
Prous Institute for Biomedical Research SA
Recursion Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc
Sentinel Oncology Ltd
Takeda Pharmaceutical Co Ltd
Taysha Gene Therapies
Triplet Therapeutics Inc
Zynerba Pharmaceuticals Inc
For queries regarding this report: https://www.researchbymarkets.com/sample-request/645836